Nystatin
- Product NDC
- 55154-4314
- 11-digit product format
- 551544314
- Labeler code
- 55154
- Product ID
- 55154-4314_c6dbde35-e0a0-4f55-be3e-471aeb0b0302
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- NYSTATIN
- Dosage form
- SUSPENSION
- Route
- ORAL
- Labeler
- Cardinal Health 107, LLC
- Application
- ANDA203621
- Marketing category
- ANDA
- Marketing start
- 2020-07-17
- Substance
- NYSTATIN
- Active strength
- 100000 [USP'U]/mL
- Pharmacologic classes
- Polyene Antifungal [EPC], Polyenes [CS]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A203621-001 | NYSTATIN | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A203621-001 | AA |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A203621-001 | NYSTATIN | 100,000 UNITS/ML | SUSPENSION / ORAL | AA | 2016-01-07 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A203621-001 | AA | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Nystatin | NYSTATIN | PAI Holdings, LLC dba PAI Pharma | 28b4e26e-206a-4e8a-abfe-774b780e91c3 | 2026-07-21 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | Cardinal Health 107, LLC | d59098da-1395-49fb-9fd6-947bbbeed56f | 2026-02-26 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | Major Pharmaceuticals | 17b9e33d-da9c-467a-bbc4-9e257727f19a | 2026-02-23 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | Cardinal Health 107, LLC | 56aca0e2-8691-4701-beba-e2315524709f | 2025-10-23 | Adverse reactions | 203621 ANDA203621 55154-4314 |
| Nystatin | NYSTATIN | PAI Holdings, LLC dba PAI Pharma | 05a8b8b6-3639-47b8-b7fc-47b105f5e6f9 | 2024-07-16 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | American Health Packaging | d8c251a6-d4da-4664-bff4-6868541d1178 | 2024-02-22 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | A-S Medication Solutions | cc3516cd-985c-489f-b4a1-8477876c5a97 | 2023-10-19 | Adverse reactions | 203621 ANDA203621 |
| Nystatin | NYSTATIN | Pharmaceutical Associates, Inc. | 31e3da10-5a7b-4bc5-8a4f-3e786b64c13a | 2022-01-13 | Adverse reactions | 203621 ANDA203621 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Nystatin
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| NYSTATIN | 100000 [USP'U]/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| BDF1O1C72E | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 312055 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 56aca0e2-8691-4701-beba-e2315524709f | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| e29fe634-dc25-094c-c77f-5d09c3eceb3e | Product name | 5 | 20260107 |
| efd58dcf-540a-4531-8766-e713129ca6f2 | Product name | 1 | 20250307 |
| e57b6340-9387-3f9a-7307-511c81791375 | Product name | 3 | 20221214 |
| 544f8e8d-6389-eeeb-9586-aa447c08dcc7 | Product name | 5 | 20210614 |
| 1629e00f-54fb-4a43-8306-b58442b23902 | Product name | 9 | 20200430 |
| 854ec07b-1cd7-a5db-235a-7aa24d3cf97a | Product name | 3 | 20180628 |
| 19b9f4c1-15e9-edcc-4c16-f01ecfb5c549 | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 55154-4314-5 | Nystatin | 5 in 1 BAG | SUSPENSION | 5 | 4 | |
| 55154-4314-5 | Nystatin | 5 mL in 1 CUP, UNIT-DOSE | SUSPENSION | 5 | 4 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 55154-4314 | NYSTATIN SUSPENSION [CARDINAL HEALTH 107, LLC] | 3 | Current NDC, 2 package rows | 20241025_56aca0e2-8691-4701-beba-e2315524709f.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 312055 | nystatin 100,000 UNT/mL Oral Suspension | PSN | 56aca0e2-8691-4701-beba-e2315524709f | 4 |
| 312055 | nystatin 100000 UNT/ML Oral Suspension | SCD | 56aca0e2-8691-4701-beba-e2315524709f | 4 |
| 312055 | nystatin 100,000 UNT/ML Oral Suspension | SY | 56aca0e2-8691-4701-beba-e2315524709f | 4 |
| 312055 | nystatin 500,000 UNT per 5 ML Oral Suspension | SY | 56aca0e2-8691-4701-beba-e2315524709f | 4 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 55154-4314-5 | 55154431405 | 5 CUP, UNIT-DOSE in 1 BAG (55154-4314-5) / 5 mL in 1 CUP, UNIT-DOSE | 2023-08-01 | No | No | Current |